The DOI matches its Crossref record; 149 of the 156 references it cites were found in a registry or an index.
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Open accessAbstract
Nanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the treatment efficacy while reducing detrimental side effects to normal tissues. Cancer drug resistance is a complicated process that involves multiple mechanisms. Here we discuss the major forms of drug resistance and the new possibilities that nanomedicines offer to overcome these treatment obstacles. Novel nanomedicines that have a high ability for flexible, fast drug design and production based on tumor genetic profiles can be created making drug selection for personal patient treatment much more intensive and effective. This review aims to demonstrate the advantage of the young medical science field, nanomedicine, for overcoming cancer drug resistance. With the advanced design and alternative mechanisms of drug delivery known for different nanodrugs including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles, overcoming various forms of multi-drug resistance looks promising and opens new horizons for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary rationale of using a suitable drug delivery system is its ability to ensure a higher and longer duration of drug bioavailability and thereby enhanced therapeutic efficacy.14,15”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“from normal stem cells versus progenitor cells, is still not clear and may vary from tumor to tumor or by tumor type [48].”
BackgroundSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Prospective identification of tumorigenic breast cancer cells
Al‐Hajj, M., Wicha, M. S., Benito‐Hernández, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,579 · cited 1×
“Tumor initiating cells were later isolated in breast carcinomas, and it was shown that only a subset of cells could be serially passaged and gave rise to both phenotypically identical and diverse cells consistent with those found in the initial tumor [40].”
ResultStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 3×
“Additional stem cell markers including CD44 [38,121] and CD133 [121] have been associated with drug resistance and may serve as potential targets for future nanodrugs to eliminate CSCs and prevent recurrence.”
BackgroundEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 1×
“Inframe deletions in exon 19 and single missense mutations account for approximately 90% of the EGFR mutations, and result in an increased sensitivity to both small molecule inhibitors, gefitinib and erlotinib [52-54].”
BackgroundNanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“It is accepted at the current stage of cancer biology that tumors at the same clinical grade and histological status are genetically heterogeneous and contain subclonal populations [33].”
BackgroundIdentification of human brain tumour initiating cells
Singh, S. K., Hawkins, C. E., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,564 · cited 1×
“Cancer stem cells have also been isolated from medulloblastoma, glioblastoma [41], ependymoma [42], colon cancer [43,44], chronic and acute myeloid leukemia [45], pancreatic cancer [46], and head and neck squamous cell carcinomas [47].”
BackgroundBonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197 · cited 1×
“showed that only a very small subset of cells that were CD34+CD38− had the ability to cause AML in NOD/SCID mice, indicating that subpopulations of cells had differential abilities to proliferate and transfer disease [39].”
Background
Flagged first, then by citations
7 of the 156 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
“To date, there has been limited success in overcoming drug resistance in cancers through the use of novel small molecule chemotherapeutics (5, 6), or nanoformulations of existing chemotherapeutics (7-9).”
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,214
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
“The primary rationale of using a suitable drug delivery system is its ability to ensure a higher and longer duration of drug bioavailability and thereby enhanced therapeutic efficacy.(14,15) Various materials with different structural forms are conjugated with drugs to prepare nano drug delivery systems.”
BackgroundEmran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Metadata
- Authors
- Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Ljubimova, Julia Y.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1866-1879
- ISSN
- 0169-409X (ISSN-L)
- PMC
- PMC5812459
- OpenAlex
- W2086374939
- Semantic Scholar
- 45ee9c859bb1f5d84491499a8da3d69d2e4c8976
- Cited by
- 733
- References
- 156
- Citations by year
- 2026: 23 · 2025: 44 · 2024: 56 · 2023: 50 · 2022: 66 · 2021: 63 · 2020: 68 · 2019: 73 · 2018: 66 · 2017: 67 · 2016: 75 · 2015: 59 · 2014: 22
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Advanced Drug Delivery Reviews (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA188743, R01CA123495, R01CA136841, U01CA151815)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanomedicine, chemoresistance, drug delivery, multidrug resistance, liposomes, polymer conjugates, micelles, dendrimers, carbon nanoparticles, metal nanoparticles, precision oncology, tumor genomic profiling
- MeSH terms
- Animals, Antineoplastic Agents, Clinical Trials as Topic, Drug Carriers, Humans, Neoplasms, Neoplastic Stem Cells, Drug Design, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Cell Line, Tumor, Nanomedicine, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
